Effect of growth hormone on high plasma levels of glucagon-like peptide-1 (GLP-1) in hypophysectomized rats

被引:4
|
作者
Tateishi, K
Kitayama, N
Ishikawa, H
Mitsudome, A
Hirose, S
机构
[1] Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140180, Japan
[2] Fukuoka Univ, Sch Med, Dept Pediat, Fukuoka 81401, Japan
[3] JCR Pharmaceut Co Ltd, Kobe, Hyogo, Japan
关键词
hypophysectomized rat; plasma GLP-1; GH; oral glucose tolerance test;
D O I
10.1055/s-2002-34994
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fasting plasma GLP-1 levels were significantly higher in hypophysectomized (hypox) rats (n=6) than in intact (normal) rats (n=7) (54.3+/-5.2 vs. 33.3+/-2.4 pmol/L, p<0.001). To examine the influence of pituitary hormones on plasma GLP-1 levels, concentrations of plasma glucose, insulin and GLP-1 after an oral glucose load to hypox rats that were given either rat growth hormone (rGH) (n=7), cortisol and thyroxine (n=7) or no substitution (n=6) were compared with those of normal rats (n=7). Plasma glucose levels in the fasting state and after the glucose ingestion were significantly lower in hypox rats, but the patterns were different from those in normal rats. Insulin levels both in the fasting state and after the glucose ingestion were significantly decreased in hypox rats and the fasting and total GLP-1 levels were significantly increased in those rats. rGH substitution significantly increased the total insulin levels in hypox rats and decreased the fasting and total GLP-1 levels closely to levels in normal rats, while substitution with cortisol and thyroxine failed to introduce such a significant effect. These results suggested that secretion of GLP-1 might be influenced by the function of GH.
引用
收藏
页码:361 / 363
页数:3
相关论文
共 50 条
  • [31] Nesfatin-1 and glucagon-like peptide-1(GLP-1) levels in Parkinson's disease and their effect on oxidative processes
    Emir, G.
    Unal, Y.
    Yilmaz, N.
    Tosun, K.
    Kutlu, G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 574 - 574
  • [32] Can glucagon-like peptide-1(GLP-1) analogues make neuroprotection a reality?
    Maryna V.Basalay
    Sean M.Davidson
    Derek M.Yellon
    Neural Regeneration Research, 2020, 15 (10) : 1852 - 1853
  • [33] Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
    Unger J.R.
    Parkin C.G.
    Diabetes Therapy, 2011, 2 (1) : 29 - 39
  • [34] Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons
    Kawatani, Masahiro
    Yamada, Yuichiro
    Kawatani, Masahito
    PEPTIDES, 2018, 107 : 68 - 74
  • [35] Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands
    Tanday, Neil
    Flatt, Peter R.
    Irwin, Nigel
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 526 - 541
  • [36] The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis
    Li, Ya-Kun
    Ma, Dong-Xia
    Wang, Zhi-Min
    Hu, Xiao-Fan
    Li, Shang-Lin
    Tian, Hong-Zhe
    Wang, Meng-Jun
    Shu, Yan-Wen
    Yang, Jun
    PHARMACOLOGICAL RESEARCH, 2018, 131 : 102 - 111
  • [37] Somatostatin is a major, paracrine regulator of glucagon-like peptide-1 (GLP-1) secretion
    Hansen, L
    Mineo, H
    Bisgaard, T
    Jorgensen, PN
    Holst, JJ
    DIABETOLOGIA, 1997, 40 : 498 - 498
  • [38] Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier
    Abba J. Kastin
    Victoria Akerstrom
    Weihong Pan
    Journal of Molecular Neuroscience, 2002, 18 : 7 - 14
  • [39] Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists
    Mabilleau, Guillaume
    Pereira, Marie
    Chenu, Chantal
    JOURNAL OF ENDOCRINOLOGY, 2018, 236 (01) : R29 - R42
  • [40] Glucagon-like peptide-1 (GLP-1) is a powerful inhibitor of gastric emptying in man
    Näslund, E
    Skogar, S
    Grybäck, P
    Jacobsson, H
    Holst, JJ
    Hellström, PM
    GASTROENTEROLOGY, 1998, 114 (04) : A810 - A810